Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis
NCT ID: NCT06284265
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
632 participants
INTERVENTIONAL
2023-10-16
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis
NCT06391164
A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections
NCT06940622
Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
NCT00921024
High Strength Cranberry Supplementation for Prevention of Recurrent Urinary Tract Infection
NCT03042273
A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.
NCT00527917
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The trial includes female outpatients aged 18 years or older with typical symptoms of chronic bacterial cystitis. The severity of typical symptoms of recurrence (exacerbation) should be 7 points or more according to the subscale "Typical symptoms" of the scale "Acute Cystitis Symptom Scale" (ACSS).
At Visit 1 (Day 1), after signing the patient information sheet and the informed consent form for participation in the clinical trial, complaints and medical history are collected, a physical examination is performed, and the severity of typical symptoms of cystitis is assessed using ACSS, collection of urine biosamples for urine analysis with microscopy and bacteriological examination (for identification the sensitivity of microorganisms to antibiotics), ultrasound examination of the urinary system (kidneys, bladder), and concomitant therapy is recorded.
Urinalysis, general and biochemical blood tests are planned in at least 190 patients.
If the patient meets inclusion criteria and does not meets exclusion inclusion criteria at Visit 1 (Day 1), the patient is randomized to one of two groups: patients of Group 1 take Phosphomycin (3 g once) and Raphamin according to the therapeutic and preventive regimen for 10 days; patients of Group 2 use Phosphomycin (3 g once) and Placebo according to the Raphamin regimen for 10 days.
If there is no effect from treatment within 48 hours or phosphomycin-resistant strains are detected, the physician conducts unscheduled visit and gives the patient an alternative drug Cefixime (400 mg). Cefixime is taken 1 times a day at a dose of 400 mg for 5 days or more (the duration of the course is determined by the physician).
All patients are provided with Phosphomycin, if resistance to it is detected - with alternative antibiotic Cefixime.
If microorganisms resistant to both Phosphomycin and Cefixime are detected, the patient is excluded from the trial, and the physician prescribes a treatment strategy in accordance with current standards.
In Electronic Patient Diary (EPD) the patient records the severity of typical cystitis symptoms using ACSS once a day at approximately the same time. Symptoms are recorded in the EPD from the patient's enrollment until Visit 2 (within 10 days of study drug administration), as well as during 10 days of treatment for each subsequent relapse (exacerbation).
In addition, any possible deterioration of the patient's condition (if applicable) is recorded in EDP to assess safety and record adverse events. The study physician instructs patients to complete the diary.
The first ACSS marks in the EDP are made by patient together with physician at Visit 1. EDP is available for filling throughout the patient's participation in the study. Once a week, the patients get SMS reminder: "If you have symptoms of the disease, enter them in the diary and contact the study physician. Don't forget to take your medication." In total, patient's follow-up lasts for 24 weeks. In the process of treatment and observation, 4 visits are scheduled: at day 1 (Visit 1) and day 11 (Visit 2), then at weeks 12 and 24 (Visits 3, 4). Visits 1, 2 and 4 are face-to-face (patient visits trial site); physician conducts physical examination, records symptoms and concomitant therapy, and checks the EPD. At Visit 2 (Day 11+3), the physician gives Phosphomycin/Cefixime and a study drug to patient, to treat a possible subsequent recurrence of cystitis. Blood and urine biosamples are taken from the patient who signed the ICF for taking biological samples (for safety assessment). The study drug received by the patient at Visit 1 should be returned to assess the patient's adherence to the study treatment. Phosphomycin/Cefixime also returns.
Visit 3 (Week 12 ± 3 days) is conducted by correspondence (telephone), in order to interview the patient about her condition.
In case of new recurrence of cystitis, patient contacts with trial physician by phone. On the basis of complaints and symptoms, physician makes conclusion about the onset of chronic cystitis recurrence. Patient completes ACSS in EPD. For a recurrence of cystitis, patient takes Phosphomycin (or Cefixime) and trial product (Raphamin/Placebo for 10 days). At the end of 10 days of treatment, an unscheduled face-to-face visit takes place (Day 11+3 days after the onset of recurrence), at which the patient returns the trial product and Phosphomycin/Cefixime, then the physician dispenses a new pack of trial product and Phosphomycin (or Cefixime) to treat a possible new recurrence of cystitis.
Visit 4 (Week 24 ± 3 days) is the final one; complaints are assessed, the patient undergoes a physical examination, returns the trial product and fills in a visual analogue scale (VAS), which assesses the degree of patient satisfaction with the therapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Raphamin
Take orally, do not take with meals. Keep the tablets in the mouth until completely dissolved.
On the first day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day another 1 tablet is taken 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 10 days.
Raphamin
Tablet for oral use.
Placebo
Take orally, do not take with meals. Keep the tablets in the mouth until completely dissolved. Placebo is administered according to the Raphamin regimen for 10 days.
Placebo
Tablet for oral use.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Raphamin
Tablet for oral use.
Placebo
Tablet for oral use.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with a confirmed diagnosis of chronic bacterial cystitis.
3. Patients with exacerbation of chronic cystitis based on typical symptoms of exacerbation of the disease with a severity of 7 points or more in accordance wuth ACSS.
4. The first 48 hours from the onset of exacerbation) of chronic bacterial cystitis.
5. Patients who agreed to use an acceptable method of contraception during the study (for women of reproductive potential).
6. Availability of a signed patient information sheet and informed consent form for participation in the clinical trial.
Exclusion Criteria
2. Presence of malignant neoplasms of the urinary tract, ureter stone, more than 50 ml of residual urine in the bladder, confirmed by ultrasound examination.
3. Suspicion of bladder tuberculosis.
4. Presence of indications for hospitalization due to a serious condition, macrohematuria, complicated cystitis.
5. Decompensation of diabetes mellitus, immunodeficiency of any etiology, malignant cancer of any localization, severe circulatory insufficiency (cardiovascular disease with functional class IV according to the classification of the New York Heart Association, 1964).
6. Unstable angina pectoris or myocardial infarction within the previous 6 months.
7. Chronic kidney disease (classes С3-5 А3).
8. Hepatic impairment (Child-Pugh class C).
9. Patients who require medicinal products prohibited for use in this study.
10. Exacerbation or decompensation of chronic conditions affecting the patient's ability to participate in the clinical trial.
11. Malabsorption syndrome, including congenital or acquired lactase deficiency or other disaccharidase insufficiency, galactosemia.
12. Hypersensitivity to any component of the medicinal products used in the treatment.
13. Pregnancy, breastfeeding; childbirth less than 3 months prior to study enrollment, unwillingness to comply with contraceptive methods during the study.
14. The medications listed in the Prohibited Concomitant Medication section were administered within 4 weeks prior to enrollment.
15. Patients who, from the investigator's point of view, will not comply with the observation requirements of the study or comply with the administration of the study drug.
16. History of mental diseases, alcoholism, or drug abuse that, in the investigator's opinion, may interfere with the successful completion of trial procedures.
17. Participation in other clinical trials within 3 months prior to enrollment.
18. The patient belongs to the investigational site personnel directly involved in the study, closest relatives of the investigator. The closest relatives are defined as spouse, parents, children or siblings, regardless of whether they are natural or adopted.
19. The patient works for the company OOO "NPF "MATERIA MEDICA HOLDING", being an employee of the company, a temporary contract worker or an appointed official responsible for performing the trial, or their close relative.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Materia Medica Holding
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scientific Center for Family Health and Human Reproduction Problems/Reproductive Health Department
Irkutsk, , Russia
Kazan State Medical University/Professor's clinic
Kazan', , Russia
LLC "Fenareta" Women's and Men's Health Clinic"
Kemerovo, , Russia
City Clinical Hospital #15 named after O.M. Filatov Department of Health of Moscow
Moscow, , Russia
City Clinical Hospital # 13/Gynecology Department # 1
Moscow, , Russia
Clinical Hospital # 85 of the Federal Medical and Biological Agency/Central polyclinic
Moscow, , Russia
Research Institute of Rheumatology named after V.A. Nasonova
Moscow, , Russia
National Medical Research Center for Obstetrics, Gynecology and Perinatology named after V.I. Kulakov/Department of Aesthetic Gynecology and Rehabilitation
Moscow, , Russia
Peoples' Friendship University of Russia/Department of Obstetrics and Gynecology with a course in perinatology
Moscow, , Russia
Russian National Research Medical University named after N.I. Pirogov/Department of Obstetrics and Gynecology, Faculty of Medicine
Moscow, , Russia
City Clinical Hospital # 1 named after. N.I. Pirogov of the Moscow City Health Department
Moscow, , Russia
United hospital with clinic of the Administration of the President of the Russian Federation
Moscow, , Russia
City Clinical Hospital # 67 named after L.A. Vorokhobov
Moscow, , Russia
JSC "MEDSI Group of Companies"
Moscow, , Russia
Moscow State Medical and Dental University named after A.I. Evdokimov/Department of Urologya
Moscow, , Russia
Privolzhsky District Medical Center
Nizhny Novgorod, , Russia
National Medical Research Center for Radiology/Research Institute of Urology and Interventional Radiology named after. N.A. Lopatkin
Obninsk, , Russia
LLC "Urology Clinic # 1"
Penza, , Russia
City Clinical Hospital
Pyatigorsk, , Russia
Rostov Central District Hospital
Rostov, , Russia
Clinical and Diagnostic Center "Health" in Rostov-on-Don
Rostov-on-Don, , Russia
Rostov State Medical University/Department of Urology and Human Reproductive Health with a course of pediatric urology-andrology
Rostov-on-Don, , Russia
Ryazan State Medical University named after Academician I.P. Pavlov/Department of Urology with a course of surgical diseases
Ryazan, , Russia
JSC "Polyclinic Complex"
Saint Petersburg, , Russia
LLC "Medical Center Capital-Polis"
Saint Petersburg, , Russia
City Geriatric Medical and Social Center
Saint Petersburg, , Russia
LLC "BioTechService"
Saint Petersburg, , Russia
City clinic # 44
Saint Petersburg, , Russia
All-Russian Center for Emergency and Radiation Medicine named after A.M. Nikiforov/Urology department
Saint Petersburg, , Russia
St. Luke's Clinical Hospital
Saint Petersburg, , Russia
City Multidisciplinary Hospital # 2/Urology department
Saint Petersburg, , Russia
Llc "Medical Clinic"
Saint Petersburg, , Russia
Medical and sanitary unit No. 70 - branch of the St. Petersburg State Unitary Enterprise of Passenger Road Transport
Saint Petersburg, , Russia
City Polyclinic # 112
Saint Petersburg, , Russia
LLC "Research Center Eco-Safety"
Saint Petersburg, , Russia
Jsc "Northwestern Center of Evidence-Based Medicine"
Saint Petersburg, , Russia
LLC "Zvezdnaya Clinic"
Saint Petersburg, , Russia
City Hospital # 33
Saint Petersburg, , Russia
LLC "New clinic "ABIA"
Saint Petersburg, , Russia
LLC "Medical Center "PRIME ROSE"
Saint Petersburg, , Russia
City Hospital # 15
Saint Petersburg, , Russia
Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott/Department of Gynecology and Endocrinology
Saint Petersburg, , Russia
City Pokrovskaya Hospital/Department of Urology
Saint Petersburg, , Russia
City Polyclinic # 3
Saint Petersburg, , Russia
City Polyclinic # 4
Saint Petersburg, , Russia
LLC "Health Formula"
Semiluki, , Russia
Sertolovo City Hospital
Sertolovo, , Russia
LLC "Uromed"
Smolensk, , Russia
Siberian State Medical University/Faculty clinics of Siberian State Medical University
Tomsk, , Russia
Tver State Medical University/Department of Obstetrics and Gynecology
Tver', , Russia
Bashkir State Medical University/Department of Obstetrics and Gynecology # 1
Ufa, , Russia
Voronezh State Medical University named after N.N. Burdenko/Department of Urology
Voronezh, , Russia
Vsevolozhsk Clinical Interdistrict Hospital/Center for Outpatient Surgery
Vsevolozhsk, , Russia
Yaroslavl State Medical University/Department of Urology and Nephrology
Yaroslavl, , Russia
LLC "Clinic of Modern Medicine Dr. Bogorodskaya"
Yaroslavl, , Russia
LLC "Medical Center for Diagnosis and Prevention Plus"
Yaroslavl, , Russia
Regional Clinical Hospital/Urology department
Yaroslavl, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Larisa Suturina, Prof.
Role: primary
Ruslan Fatykhov, MD, PhD
Role: primary
Natalia Artymuk, Prof.
Role: primary
Felix Grigoryan, PhD
Role: primary
Sergey Levakov, Prof.
Role: primary
Inna Apolikhina, Prof.
Role: primary
Yulia Dobrokhotova, Prof.
Role: primary
Sergey Kotov, PhD, MD
Role: primary
Olga Perevozkina, MD, PhD
Role: primary
Dmitry Pushkar, Prof.
Role: primary
Vagif Atduev, Prof.
Role: primary
Natalia Galkina, MD, PhD
Role: primary
Alexander Bardin, MD
Role: primary
Ariz Gyulmamedov, MD
Role: primary
Mikhail Kogan, Prof.
Role: primary
Victor Filimonov, Prof.
Role: primary
Role: backup
Dmitry Gorelov, MD
Role: primary
Vladimir Gomberg, MD, PhD
Role: primary
Alexander Parshin, PhD
Role: primary
Farzali Farzaliev, MD
Role: primary
Vladislav Grigoriev, PhD
Role: primary
Igor Orlov, PhD
Role: primary
Maxim Bushara, MD
Role: primary
Vadim Zubarev, PhD, MD
Role: primary
Alexander Bulkin, MD
Role: primary
Anton Kurnakov, MD, PhD
Role: primary
Stanislav Sosnovsky, MD, PhD
Role: primary
Anton Boriskin, MD, PhD
Role: primary
Konstantin Dunets, MD
Role: primary
Maria Yarmolinskaya, Prof.
Role: primary
Andrey Gorelov, Prof.
Role: primary
Andrey Gurchin, MD
Role: primary
Mikhail Alekseev, MD, PhD
Role: primary
Timur Gyaurgiev, MD, PhD
Role: primary
Alexander Shvets, MD
Role: primary
Andrey Kuzmenko, Prof.
Role: primary
Nikolay Kanareikin, MD
Role: primary
Andrey Soloviev, MD, PhD
Role: primary
Svetlana Isakova, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MMH-407-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.